- Osimertinib and its role in first-line NSCLC treatment2020 | Publication without faculty affiliation
- Tagrisso (osimertinib)2016 | Publication without faculty affiliation
- Case studies of patients treated with osimertinib2019 | Second Faculty of Medicine
- Osimertinib in treating advanced non-squamous non-small cell lung cancer2022 | First Faculty of Medicine
- Osimertinib and its use in the treatment of non-small cell lung carcinoma in the Czech Republic2018 | Third Faculty of Medicine
- Tagrisso TM (Osimertinib, AZD929I)2016 | Faculty of Medicine in Pilsen
- Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study2018 | First Faculty of Medicine
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- Osimertinib - a new oral third-generation EGFR TKI2017 | Publication without faculty affiliation
- Osimertinib - zkušenosti z klinické praxe2019 | Second Faculty of Medicine
- Targeted treatment with osimertinib in the adjuvant treatment of a patient with non‐small cell lung cancer – case report2023 | Third Faculty of Medicine
- Osimertinib2017 | Third Faculty of Medicine
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Editorial2017 | Faculty of Medicine in Pilsen
- Long-term surviving patient with EGFR mutation - deletion on exon 79 and acquired resistant mutation T790 - case report2020 | Faculty of Medicine in Pilsen
- Adjuvantní léčba anti-EGFR tyrosinkinázovými inhibitory u resekovaného NSCLC a studie ADAURA – komentář2023 | First Faculty of Medicine
- Neo-/adjuvant immunotherapy and targeted therapy of non-small cell lung cancer2023 | Faculty of Medicine in Pilsen
- Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples2020 | Faculty of Medicine in Hradec Králové
- Treatment options for non-small cell lung stage III cancer2021 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Current position of afatinib in the therapy of non-small cell lung carcinoma2017 | Publication without faculty affiliation
- Afatinib - drug profile2017 | Publication without faculty affiliation
- Treatment of non-small cell lung cancer with a driver mutation2022 | Faculty of Medicine in Pilsen
- Advances in management of stage III non-small cell lung cancer2022 | First Faculty of Medicine
- Přínos tyrosinkinázových inhibitorů EGFR v adjuvantní léčbě karcinomů plic2023 | Faculty of Medicine in Pilsen
- Přínos tyrosinkinázových inhibitorů EGFR v adjuvantní léčbě karcinomu plic2023 | Faculty of Medicine in Pilsen
- Current procedures and news in the treatment of lung cancer2021 | First Faculty of Medicine